Condition (MeSH)
Dyskinesia, Drug-Induced
ClinicalTrials.gov lists 75 trials for Dyskinesia, Drug-Induced or a narrower condition beneath it. Neurocrine Biosciences has the most among industry and government lead sponsors, with 13.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
16 of the 75 trials are tagged with Dyskinesia, Drug-Induced itself; the rest are tagged with a narrower condition beneath it.
When did Dyskinesia, Drug-Induced trials start? (25)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 5 |
| 2024 | 3 |
| 2023 | 3 |
| 2022 | 2 |
| 2021 | 4 |
| 2019 | 4 |
| 2018 | 2 |
| 2017 | 6 |
| 2016 | 2 |
Showing 10 of 25 earlier years.
No forecast is made for this condition: it averages 3.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 31 months from start to primary completion across 7 trials still running at the 2026-10-09 snapshot; registered median of 22 months across 47 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Dyskinesia, Drug-Induced trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 6 |
| Phase 1/2 | 3 |
| Phase 2 | 19 |
| Phase 2/3 | 5 |
| Phase 3 | 11 |
| Phase 4 | 13 |
| Not applicable | 12 |
| Observational | 6 |
How many Dyskinesia, Drug-Induced trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 7 |
| Active, not recruiting | 1 |
| Completed | 43 |
| Terminated | 7 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Dyskinesia, Drug-Induced trials? (7)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Neurocrine Biosciences | 13 |
| Luye Pharma Group Ltd. | 4 |
| Auspex Pharmaceuticals, Inc. | 3 |
| Addex Pharma S.A. | 2 |
| Beersheva Mental Health Center | 2 |
Showing 5 of 7 sponsors.
Which drugs are being tested for Dyskinesia, Drug-Induced? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| MT-5199 | 7 |
| Valbenazine | 6 |
| SD-809 | 4 |
| Aripiprazole | 2 |
| Dipraglurant | 2 |
Showing 5 of 6 drugs.
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| LPM3770164 sustained release tablet simulant | 3 |
| IM olanzapine | 3 |
| LPM3770164 sustained release tablet | 3 |
| Levetiracetam XR | 2 |
| IR Risperidone | 2 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Dyskinesia, Drug-Induced trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Schizophrenia | 18 | 6 |
| Pneumonia | 11 | 5 |
| Suicidal ideation | 10 | 7 |
| Chronic obstructive pulmonary disease | 9 | 6 |
| Depression | 7 | 5 |
Showing 5 of 10 adverse events.
Which publications cover Dyskinesia, Drug-Induced? (176)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Efficacy and safety of Tianqi Pingchan Granule, a compound Chinese herbal medicine, for levodopa-induced dyskinesia in Parkinson's disease: A randomized double-blind placebo-controlled trial. | Journal of integrative medicine | 2024 | Yes |
| Home-based transcranial static magnetic field stimulation of the motor cortex for treating levodopa-induced dyskinesias in Parkinson's disease: A randomized controlled trial. | Brain stimulation | 2022 | Yes |
| Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study. | Journal of Parkinson's disease | 2021 | Yes |
| Abnormal cortical facilitation and L-dopa-induced dyskinesia in Parkinson's disease. | Brain stimulation | 2019 | Yes |
| Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease. | CNS drugs | 2018 | Yes |
Showing 5 of 176 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.